Ed Kaye, Stoke Therapeutics CEO
Stoke Therapeutics unveils more data on studies of Dravet drug, hinting at improvements to cognition and behavior
Stoke Therapeutics presented more data on its investigational Dravet syndrome treatment on Tuesday morning, saying it helped reduce seizures and improve certain cognitive and behavioral …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.